Started in Oxford

Since 1997, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and has spun out a new company every two months on average.

Over £266 million in external investment has been raised by Oxford University Innovation spinouts since 2000, and five are currently listed on London’s AIM market.

The creation of these new spinout companies also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

AnDy marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from our environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering.

Incorporated in April 2015

Origin: Oxford University, Department of Zoology

Aurox was established to research, develop, manufacture and commercially exploit products in the field of confocal microscopy and automated pathology slide scanners.

Incorporated in July 2006

Origin: Oxford University, Department of Engineering Science

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Incorporated in November 2002

Origin: Oxford University, Department of Pathology

Using phase change materials for smart glazing and displays.

Incorporated in November 2015

Origin: Oxford University, Department of Materials

Advanced materials and technologies in safe, lightweight, high performance hydrogen storage technology.

Incorporated in January 2011

Origin: Oxford University, Science and Technology Facilities Council

Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Incorporated in September 2016

Origin: Oxford University, Ophthalmology

ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.

Incorporated in June 2007

Origin: Oxford University, Nuffield Division of Clinical and Laboratory Sciences

Using leading edge human biomimetic platforms to test and develop therapeutics for serious human diseases.

Incorporated in July 2009

Origin: Oxford University, Institute of Biomedical Engineering

Crysalin develop a protein lattice technology that is founded on a novel form of highly ordered materials, crysalins, that are produced through modification of naturally occurring protein building blocks.

Incorporated in June 2007

Origin: Oxford University, Department of Biochemistry

Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Incorporated in October 2006

Origin: Oxford University, Division of Clinical Neurology/Weatherall Institute of Molecular Medicine

Deontics is software which guides doctors and patients through the scientific and clinical decision making.

Incorporated in August 2015

Origin: Oxford University, Department of Engineering Science

Designer Carbon Materials, Developing advanced nanomaterials for a range of applications, including energy harvesting, bio-sensing and quantum nanoelectronics.

Incorporated in April 2014

Origin: Oxford University, Department of Materials

DiffBlue is a world leader in automated test generation. Their products have been developed with industry partners over the last ten years and replace the manual process of writing tests.

Incorporated in March 2016

Origin: Oxford University, Department of Computer Science

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

Incorporated in December 2004

Origin: Oxford University, Department of Earth Sciences

EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.

Incorporated in April 2016

Origin: Oxford University, Neuroscience


Ready to get in touch?

Contact Us
© Oxford University Innovation